Gene transfer and the treatment of haematological malignancy

Journal of Internal Medicine

Volumn 249, Issue 4, 2001, Pages 345-358

  Brenner, M K ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b MC3 3320 ^*  (United States)

Author keywords

Cytotoxic T cell; Gene transfer; Leukaemia

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ACICLOVIR; CD40 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B1; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA B7 ANTIGEN; HYDROXYLAMINE; INTERLEUKIN 2; LYMPHOTACTIN; NITROREDUCTASE; NUCLEOSIDE; PRODRUG; T LYMPHOCYTE RECEPTOR; THYMIDINE KINASE; TUMOR VACCINE; VALACICLOVIR;

ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG SPECIFICITY; ENZYME METABOLISM; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HOST CELL; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MARKER GENE; NONHUMAN; PRIORITY JOURNAL; STEM CELL;

ANIMALS; ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; CANCER VACCINES; EPSTEIN-BARR VIRUS INFECTIONS; GANCICLOVIR; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS; HODGKIN DISEASE; HUMANS; LEUKEMIA; LYMPHOPROLIFERATIVE DISORDERS; PRODRUGS; T-LYMPHOCYTES, CYTOTOXIC; VIRUS LATENCY;

EID: 0035731762     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2001.00807.x     Document Type: Conference Paper

References (85)

1. Retrovirally marked CD34-enriched peripheral blood and marrow cells contribute to long term engraftment after autologous transplantation
2. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients
3. Engraftment of gene-modified umbilical cord blood in neonates with adenosine deaminase deficiency
4. T lymphocyte-directed gene therapy for ADA- SCID. Initial trial results after 4 years
5. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector
6. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
7. Induction of apoptosis in myeloid leukaemic cells by ribozymes targeted against AML1/MTG8
8. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias
9. Myb targeted therapeutics for the treatment of human malignancies
10. Cancer therapy based on p53
11. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor
12. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminse
13. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene
14. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)
15. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
16. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
17. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy
18. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified
19. Combined chemokine and cytokine gene transfer enhances antitumor immunity
20. Gene transfer as cancer therapy
21. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans
22. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells
23. CD40 ligand induces an anti-leukemia immune response in vivo
24. A novel herpes vector for the high efficiency transduction of normal and malignant human hemopoietic cells
25. Efficient gene transfer into human CD34 (+) cells by a retargeted adenovirus vector
26. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study
27. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
28. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma
29. IL-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma
30. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex-vivo granulocyte-macrophage colony-stimulating factor gene transfer
31. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
32. Future strategies toward the cure of indolent B-cell malignancies. Molecular genetic approaches
33. Adoptive immunotherapy with donor lymphocyte transfusions
34. The graft-versus-leukemia effects of allogeneic cell therapy
35. Adoptive immunotherapy of EBV lymphoproliferative diseases
36. Potential immunogenicity of oncogene and tumor supressor gene products
37. Graft-versus-host reactions and bone marrow transplantation
38. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
39. Epstein-Barr virus-associated peripheral T-cell lymphoma of activated CD8 phenotype
40. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease
41. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients
42. Early identification of Epstein-Barr virus-associated post-transplant lymphoproliferative disease
43. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells
44. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features
45. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
46. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts
47. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation
48. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation
49. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
50. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
51. Mutation in EBV produces immunoblastic lymphoma unresponsive to CTL immunotherapy
52. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia
53. Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease
54. Tumor-specific T-bodies: Towards clinical application
55. In vivo antitumor activity of T cells redirected with chimeric antibody/T cell receptor genes
56. Virus and tumor-specific cytotoxic T cell therapy
57. The TCR zeta-chain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes
58. T cell activation determined by T cell receptor number and tunable thresholds
59. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors
60. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma
61. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor
62. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30
63. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product
64. Establishing chemoresistance in hematopoietic progenitor cells
65. Multidrug resistance
66. Expression of retroviral vectors containing the human MDR1 cDNA in hematopoietic cells of transplanted mice
67. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis (2-chloroethyl) -1-nitrosourea, a chemotherapeutic alkylating agent
68. In vivo selction of DHFR-modified murine hemopoietic progenitors by combined therapy with trimetrexate and thymidine transport inhibitors
69. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to post-transplant hematopoietic recovery following intensive systemic therapy
70. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation
71. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells
72. Gene marking
73. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: Results of MRC AML 10 trial
74. Autologous stem cell transplantation in acute myelocytic leukemia
75. The biology and clinical uses of blood stem cells
76. Autologous stem-cell transplantation for solid tumors in adults
77. Autologous hematopoietic cell transplantation in non-Hodgkin's lymphoma
78. Should we purge?
79. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangements in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation
80. Gene-marking to trace origin of relapse after autologous bone marrow transplantation
81. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML
82. Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia
83. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission
84. Gene therapy of human severe combined immunodeficiency (SCID) -X1 disease
85. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients